Evidence map›Paper›PMID 29499174›Full record

ArticleAmerican journal of ophthalmology2018

Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration.

Saleema Kherani, Adrienne W Scott, Adam S Wenick, Ingrid Zimmer-Galler, Christopher J Brady, Akrit Sodhi, Catherine Meyerle, Sharon D Solomon, Rimsha Shaukat, Roomasa Channa and 4 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03699618 (Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03699618 terminatednot on this mapstarted 2019, after this paper: background citation

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

TypeobservationalSponsorJohns Hopkins UniversityRan2019 to 2020Enrolled1ConditionsSubmacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular DegenerationArmsAnti-VEGF, Hemorrhage displacement + Anti-VEGF
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Saleema KheraniThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adrienne W ScottThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adam S WenickThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ingrid Zimmer-GallerThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Christopher J BradyThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Akrit SodhiThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Catherine MeyerleThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sharon D SolomonThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Rimsha ShaukatThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Roomasa ChannaThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Olukemi AdeyemoThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
James T HandaThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jiangxia WangJohns Hopkins Biostatistics Center, Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Peter A CampochiaroThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4R01EY025705 · NEI · UNIVERSITY OF MARYLAND BALTIMORE · PI MONTANER, SILVIA V · 2016 to 2020
$2.6M
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal DiseaseR01EY029750 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2019 to 2023
$2.6M
NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY025705NEI NIH HHS R01 EY029750
6 · The paper itself

Abstract

purposeTo identify factors influencing visual outcome in patients with neovascular age-related macular degeneration (NVAMD) and subfoveal hemorrhage (SFH) treated with anti-vascular endothelial growth factor (VEGF) agents.

designRetrospective case series.

methodsAnti-VEGF-treated eyes with SFH > 1 disc area (DA) were identified (n = 16) and changes in visual acuity (VA) and central subfield thickness (CST) from baseline to last follow-up, along with SFH area, thickness, minimum distance from fovea to SFH border, and time to resolution, were determined.

resultsAt baseline, mean (± standard error of the mean) size and thickness of SFH were 14.9 ± 2.8 DA and 386.6 ± 46.9 μm, and mean Snellen VA and CST were 20/250 and 591.7 ± 57.0 μm. Median follow-up was 47.6 months. While more than 50% of patients had VA ≤ 20/200 at baseline and all time points through week 48, the percentage of patients with VA ≥ 20/50 increased to 30%-40% at months 6 and 12 and remained stable through month 48. Spearman rank correlation demonstrated 2 independent variables that correlated with good visual outcome, smaller area of SFH at baseline (r = -0.630; P = .009), and high frequency of anti-VEGF injections (r = 0.646; P = .007). In exceptional patients with good visual outcome despite large baseline SFH, shortest distance between the fovea and hemorrhage border significantly correlated with baseline VA (r = -0.503, P = .047) and final VA (r = -0.575, P = .02).

conclusionsPatients with NVAMD and thick SFH, but short distance between fovea and uninvolved retina, can have good visual outcomes when given frequent anti-VEGF injections.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsChoroidal NeovascularizationFemaleFluorescein AngiographyFovea CentralisHumansIntravitreal InjectionsMaleMiddle AgedRetinaRetinal HemorrhageRetinal Pigment EpitheliumRetrospective StudiesTomography, Optical CoherenceAngiogenesis InhibitorsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID29499174
PMCPMC10020831
OpenAlexW2788811346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.